Mostrar el registro sencillo del ítem

dc.contributor.authorVela, Paloma
dc.contributor.authorSanchez-Piedra, Carlos
dc.contributor.authorPerez-Garcia, Carolina
dc.contributor.authorCastro-Villegas, María C
dc.contributor.authorFreire Gonzalez, Mercedes 
dc.contributor.authorMateo, Lourdes
dc.contributor.authorDíaz-Torné, Cesar
dc.contributor.authorBohorquez, Cristina
dc.contributor.authorBlanco-Madrigal, Juan M
dc.contributor.authorRos-Vilamajo, Inmaculada
dc.contributor.authorGómez, Silvia
dc.contributor.authorCaño, Rocio
dc.contributor.authorSánchez-Alonso, Fernando
dc.contributor.authorDíaz-González, Federico
dc.contributor.authorGómez-Reino Carnota, Juan Jesús 
dc.date.accessioned2022-03-16T08:38:25Z
dc.date.available2022-03-16T08:38:25Z
dc.date.issued2020
dc.identifier.issn1478-6354
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32539800es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16270
dc.description.abstractOBJECTIVES: To assess whether age, at the beginning of biologic treatment, is associated with the time a first adverse event (AE) appears in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA). METHODS: All patients in the BIOBADASER registry diagnosed with RA, AS, and PsA, and classified as young (< 25 years old), adult (25-64 years old), elderly (65-75 years old) or very elderly (> 75 years old) at start of biological treatment were included. Factors associated with the appearance of a first AE using adjusted incidence rate ratios (IRR) (Poisson regression) were analyzed. Survival to first AE was studied by Kaplan-Meier analysis and hazard ratios (HR) by Cox regression. RESULTS: 2483 patients were included: 1126 RA, 680 PsA, and 677 AS. Age group stratification was as follows: 63 young, 2127 adults, 237 elderly, and 56 very elderly. Regression model revealed an increased probability of suffering a first AE at age 65 years or older [IRR elderly: 1.42 (CI95% 1.13-1.77)]. Other characteristics associated with AE were female gender, the use of DMARDs, including methotrexate, the presence of comorbidities, and the time of disease duration. Factors that had the greatest impact on survival over a first AE were age > 75 years [HR 1.50 (1.01-2.24)] and female gender [HR 1.42 (1.22-1.64)]. CONCLUSION: Age at the start of treatment and female gender are key factors associated with the appearance of a first AE with biologics. Other factors related to patient status and treatment were also associated with a first AE in rheumatic patients treated with biologics.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshAdult*
dc.subject.meshMiddle Aged*
dc.subject.meshHumans*
dc.subject.meshYoung Adult*
dc.subject.meshMethotrexate*
dc.subject.meshAged*
dc.titleInfluence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III registeren
dc.typeJournal Articlees
dc.authorsophosVela, Paloma;Sanchez-Piedra, Carlos;Perez-Garcia, Carolina;Castro-Villegas, María C;Freire, Mercedes;Mateo, Lourdes;Díaz-Torné, Cesar;Bohorquez, Cristina;Blanco-Madrigal, Juan M;Ros-Vilamajo, Inmaculada;Gómez, Silvia;Caño, Rocio;Sánchez-Alonso, Fernando;Díaz-González, Federico;Gómez-Reino, Juan J
dc.identifier.doi10.1186/s13075-020-02231-x
dc.identifier.pmid32539800
dc.identifier.sophos36142
dc.issue.number1es
dc.journal.titleARTHRITIS RESEARCH & THERAPYes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Reumatoloxíaes
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296933/pdf/13075://2020://Article://2231.pdfes
dc.rights.accessRightsopenAccess
dc.subject.decsanciano*
dc.subject.decsmetotrexato*
dc.subject.decsadulto joven*
dc.subject.decsmediana edad*
dc.subject.decshumanos*
dc.subject.decsadulto*
dc.subject.keywordCHUACes
dc.typefidesArtículo de Revisiónes
dc.typesophosArtículo de Revisiónes
dc.volume.number22es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional